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NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Osteitis
fibrosa is a common bone injury associated with secondary hyperparathy-
roidism (2°HPT). NPS R-568 is a phenylalkylamine derivative that acts as
an agonist at the cell-surface Ca21 receptor (“calcimimetic”) and inhibits
parathyroid hormone (PTH) secretion. In the present study, we tested
whether NPS R-568 could ameliorate osteitis fibrosa in partially nephrec-
tomized (Nx) rats with 2°HPT. Six months after surgery, Nx rats had
developed mild but progressive 2°HPT and osteitis fibrosa. Two groups of
Nx rats received NPS R-568 (3 and 30 mg/kg body wt z day) by daily gavage
for 30 days, which led to a dose-related decrease in serum PTH levels and
to a marked reduction in peritrabecular fibrosis (0.96 6 0.49% to , 0.1%).
Furthermore, 2°HPT was associated with decreases in volumetric cortical
bone mineral density (vCtBMD) and in cortical bone stiffness at the
femoral midshaft. NPS R-568 significantly restored the deficits in
vCtBMD and stiffness. These results indicate that NPS R-568 has
beneficial effects on bones with osteitis fibrosa by normalizing serum PTH
levels.
Secondary hyperparathyroidism (2°HPT) and renal osteodys-
trophy are common complications of chronic renal insufficiency
(CRI) [1, 2]. The former is characterized by hyperplasia of the
parathyroid glands and chronically elevated circulating levels of
parathyroid hormone (PTH) [3]. The latter comprises a number
of histologically distinct bone abnormalities that can be classified
as either high turnover (osteitis fibrosa, mild, and mixed type) or
low turnover bone diseases (osteomalacia and aplastic/adynamic
type) [4, 5].
Osteitis fibrosa is a prevalent high turnover bone disease in CRI
and is characterized by increased bone resorption, extensive
osteoblastic activity and peritrabecular bone marrow fibrosis [1,
2]. Osteitis fibrosa is a typical 2°HPT-related bone disease that is
caused by chronically elevated plasma levels of PTH [1, 2]. The
area of bone marrow fibrosis is correlated with the plasma levels
of PTH [6], and total or partial parathyroidectomy reverses the
development of osteitis fibrosa [7, 8]. Experimental osteitis fibrosa
can be induced by infusing animals with high doses of PTH [9].
Furthermore, calcitriol therapies that reduce circulating levels of
PTH can also ameliorate osteitis fibrosa [10, 11]. All of these
observations suggest that osteitis fibrosa is linked to 2°HPT and
osteitis fibrosa could be treated by lowering plasma levels of PTH.
The cell-surface Ca21 receptor on parathyroid cells regulates
the secretion of PTH [12, 13], thereby providing a novel target for
therapeutic agents to control 2°HPT (“calcimimetics”) [14, 15].
Recently, we identified NPS R-568, an orally-active phenylal-
kylamine compound, that acts as an agonist at the Ca21 receptor
and suppresses PTH secretion [14, 15]. When given to animals [16,
17] or humans [18, 19], NPS R-568 is well tolerated and produces
a dose-dependent decrease in circulating levels of PTH. Since it
suppresses PTH secretion, NPS R-568 may ameliorate osteitis
fibrosa [20]. To test this hypothesis, we explored the effects of
NPS R-568 on bone structure and strength in partially nephrec-
tomized (Nx) rats with 2°HPT. The Nx rats developed osteitis
fibrosa, which was associated with loss of cortical bone strength.
We show that treatment with NPS R-568 reduces serum PTH
levels, eliminates osteitis fibrosa, and returns cortical bone
strength towards normal.
METHODS
Materials
NPS R-568, N-(3-[2-chlorophenyl]-propyl)-(R)-a-methyl-3-
methoxybenzylamine HCl, referred to as KRN568 in Japan, was
synthesized by OREAD Laboratories, Inc. (Lawrence, KS, USA).
Cyclodextrin (2-hydroxypropyl-b-cyclodextrin) was obtained from
RBI (Natick, MA, USA), calcein was from TCI (Tokyo, Japan),
and tetracycline-HCl was from Sigma (St. Louis, MO, USA).
Animals, diets and surgery
Male Sprague-Dawley rats, 5 weeks of age and weighing 110 to
130 g (Charles River, Tokyo, Japan) were allowed free access to
a standard diet containing 1.2% Ca, 1.1% P, 25% protein and 2.5
IU vitamin D3/g (CLEA, Tokyo, Japan) and water. After an
acclimatization period of one week, the animals were divided in
two groups. One group was subjected to a partial nephrectomy
(Nx) while the other group was sham-operated (Sham). The Nx
was carried out using a two step procedure under ether anesthe-
sia; one branch of the left renal artery was ligated and was
followed, six days later, by a right total nephrectomy.
Experimental protocol
Twenty-five weeks following right nephrectomy or sham oper-
ation, the rats were weighed and placed in a metabolism cage for
the collection of a 24-hour urine sample. A blood sample was
1 See Editorial by Sherrard; p 511
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collected from the tail artery. The nephrectomized rats were
divided into three groups each composed of eight animals that
were matched with respect to body weight, BUN, and serum PTH
levels. The treatment groups were as follows: Group 1, Sham-
Vehicle; Group 2, Nx-Vehicle; Group 3, Nx-NPS R-568 (3 mg free
base/kg body wt z day); Group 4, Nx-NPS R-568 (30 mg free
base/kg body wt z day). NPS R-568 was dissolved in a 10% aqueous
solution of cyclodextrin and was administered by p.o. gavage
between 09:00 and 10:00 hour daily for 30 days. To label the
bone-forming surfaces, each animal was injected with calcein (15
mg/kg body wt, i.p.) on day 9 and tetracycline (20 mg/kg body wt,
i.p.) on day 18. A second 24-hour urine collection was made on
the last day of treatment (day 30). Rats were anesthetized with
ether and euthanized by aortic puncture on day 31.
At necropsy, the tibiae were dissected and fixed in 10%
buffered neutral formalin for subsequent bone histomorphom-
etry. The femurs were detached from the body at the hip joint and
stored in 50% ethanol/saline at 4°C for bone densitometry and
biomechanical analyses. One animal in Group 4 died of severe
uremia during the experiment; no data from this animal are
included.
Serum and urine chemistry
Serum and urine samples were stored at 280°C until analyses.
Alkaline phosphatase, creatinine, calcium, and phosphorus were
determined using standard laboratory methods with an automated
multiparametric analyzer (Hitachi 717, Tokyo, Japan). Serum
PTH was measured using a rat PTH-(1-34) immunoradiometric
assay (Nichols Institute Diagnostics, San Juan Capistrano, CA,
USA), and 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] using a calf
mammary gland radioreceptor assay (Yamasa, Tokyo, Japan).
Cancellous bone histomorphometry
The tibiae were subjected to Villanueva’s staining, dehydrated
and embedded in methylmethacrylate without decalcification.
Sagittal sections (10 mm thick) of the tibiae were cut using a Minot
microtome. Fibrosis volume (Fb.V/TV) was determined at the
secondary spongiosa in the proximal metaphysis. Osteitis fibrosa
was diagnosed according to Sherrard et al by Fb.V/TV . 0.5% [4].
Since the labeled surface in the metaphysis was destroyed by
osteitis fibrosa, all other histomorphometric analyses were per-
formed in the proximal tibial epiphysis. Trabecular bone was
analyzed in areas .0.3 mm from the surrounding endocortical
surface and were performed using the Osteoplan system II
(Kontron, Mu¨nchen, Germany) as described previously [21, 22].
Standard histomorphometrical nomenclatures, symbols, and cal-
culations according to the ASBMR committee were used [23].
Cortical bone mineral density, biomechanics and morphometry
The femurs were dissected free of soft tissues and subjected to
dual energy X-ray absorptiometry (DEXA). The femur was
scanned with a line space of 1 mm and a scanning speed of 10
mm/second using a DEXA (DCS-600, Aloka; Tokyo, Japan).
Diaphyseal bone mineral content (BMC; mg/mm bone length)
was analyzed at the midpoint region. Volumetric cortical bone
mineral density (vCtBMD; g/cm3) was calculated by vCtBMD 5
BMC/Ct.Ar, where Ct.Ar is the cross-sectional cortical area
(mm2) determined by subsequent morphometry. Triplicate exam-
ination of BMD of six different femurs, with a new placement
after each run, showed the intermeasurement coefficient of
variation was 3.6%.
Bone strength was determined by three-point bending test using
a biomechanical analyzer (MZ500D; Maruto, Tokyo, Japan) [24,
25]. A femur was placed on two supporting bars 20 mm apart and
Table 1. Serum chemistries, creatinine clearance, and body weight in
sham-operated (Sham) and partially nephrectomized (Nx) rats treated
with vehicle or NPS R-568 for 30 days.
Sham
Vehicle
Nx
Vehicle
NPS R-568
3 mg/kg z day
NPS R-568
30 mg/kg z day
Serum
Creatinine
mg/dl
0.32 6 0.01 1.55 6 0.45a 0.89 6 0.17a 1.09 6 0.16a
Calcium
mg/dl
9.43 6 0.09 9.25 6 0.19 9.22 6 0.13 8.40 6 0.21a,b
Phosphorus
mg/dl
6.27 6 0.08 7.12 6 0.56 6.27 6 0.13 6.94 6 0.39
ALP IU/liter 263 6 15 276 6 37 252 6 20 228 6 21
1,25(OH)2D3
pg/ml
24.5 6 1.3 22.8 6 4.7 21.5 6 3.1 18.3 6 4.2
Urine
CCr ml/min z
kg body wt
5.95 6 0.28 2.20 6 0.53a 2.69 6 0.37a 2.11 6 0.31a
Weight
Body weight g 697 6 26 616 6 29 642 6 29 641 6 17
N 8 8 8 7
Abbreviations are: ALP, alkaline phosphatase; CCr, creatinine clear-
ance. Values are means 6 SEM and are from samples collected 24 hours
after the last dose of NPS R-568.
a P , 0.01 vs. Sham-Vehicle group
b P , 0.05 vs. Nx-Vehicle group
Table 2. Bone histomorphometry in the proximal tibia of sham-
operated (Sham) and partially nephrectomized (Nx) rats treated with
vehicle or NPS R-568 for 30 days
Sham
Vehicle
Nx
Vehicle
NPS R-568
3 mg/kg z day
NPS R-568
30 mg/kg z day
Static (epiphysis)
BV/TV % 42.1 6 3.3 31.9 6 3.3 36.4 6 4.2 38.7 6 1.3
OV/BV % 0.5 6 0.1 6.9 6 1.8b 4.7 6 1.8b 3.0 6 1.0a
Ob.S/BS % 16.0 6 0.8 22.7 6 2.2a 20.2 6 0.7a 19.3 6 0.9a
Oc.S/BS % 6.4 6 1.0 15.2 6 1.2b 12.4 6 1.5a 11.4 6 1.7
Dynamic
(epiphysis)
BFR/TV %/year 18 6 3 58 6 12a 59 6 17a 42 6 14
BFR/BV %/year 43 6 6 199 6 55b 145 6 27a 104 6 31
MS/BS % 11.8 6 2.6 12.8 6 3.1 13.6 6 3.2 16.0 6 2.9
MAR mm/day 1.06 6 0.07 2.58 6 0.72 1.48 6 0.12 1.38 6 0.15
Fibrosis
(metaphysis)
Fb.V/TV % 0 0.96 6 0.49 ,0.1 ,0.1
Osteitis fibrosa
N/N
0/8 3/8 0/8 0/7
Abbreviations are: BV/TV, bone volume; OV/BV, osteoid volume;
Ob.S/BS, osteoblast surface; Oc.S/BS, osteoclast surface; BFR/TV and
BFR/BV, bone formation rates at tissue volume- and bone volume-
referent, respectively; MS/BS, mineralizing surface; MAR, mineral appo-
sition rate; Fb.V/TV, fibrosis volume. Osteitis fibrosa was defined as
Fb.V/TV .0.5% (N of affected animals/total N of animals).
a P , 0.05, b P , 0.01; vs. Sham-Vehicle group
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deflected at its midpoint using a loader driven at a constant speed
of 10 mm/min until fracture occurred. The load-displacement
curve of the loader was fed to an x-y recorder and stiffness was
obtained as the slope of the elastic region and ultimate load as the
peak of the curve. The load-displacement relationship was also
transformed to stress-strain relationship according to Turner and
Burr [25], and elastic modulus was calculated as the slope of the
elastic region and ultimate stress as the peak of the curve. The
cross sectional image of cortical bone was read under a micro-
scope equipped with a micrometer as described previously [26].
Cortical width, cortical area, and cross sectional moment of
inertia were calculated on the assumption that femoral cross
sections are elliptically shaped [26].
Statistics
Results are given as means 6 SEM. Two-group comparison was
performed using Mann-Whitney U-test. Multiple comparisons
were performed using a non-parametric Dunnett’s test (Steel’s
test). The significance of correlation was tested using Pearson’s
correlation coefficient analysis. P , 0.05 was taken to indicate
statistical significance.
RESULTS
Serum and urine chemistries
At the start of treatment (baseline point), renal function in Nx
rats, as assessed by creatinine clearance, was reduced by 50% than
that in the Sham controls (2.3 6 0.3 vs. 5.3 6 0.3 ml/min z kg body
wt). Creatinine clearance did not decrease further during the
course of the study and remained comparable among the three Nx
groups (Table 1). There were no significant differences in serum
phosphorus or alkaline phosphatase levels among the groups at
the end of the study. Despite the decrease in creatinine clearance,
serum 1,25(OH)2D3 levels in the Nx groups were comparable to
those of the Sham controls and were unaffected by NPS R-568.
Body weight was 11% lower in Nx groups than that in the Sham
controls, but there were no significant differences among the Nx
groups.
The Nx rats developed mild but progressive 2°HPT (Fig. 1). At
the baseline point, serum PTH levels in Nx rats were 2.4-fold
higher than those in the Sham controls, indicating the evolution of
mild 2°HPT at the start of treatment. During the course of the
study, a modest progression of 2°HPT was observed as docu-
mented by a further 70% increase in serum PTH levels in
vehicle-treated Nx animals (95 6 22 to 165 6 94 pg/ml at the end
point). In contrast, no progression of 2°HPT was observed in the
Nx rats treated with NPS R-568 (Fig. 1). On day 16, one hour after
dosing, low and high doses of NPS R-568 reduced serum PTH
levels to 13 6 2% and 11 6 1% of the levels before administra-
tion, respectively, verifying the suppressive effect of NPS R-568 on
PTH secretion. The reduction in serum PTH levels was accom-
panied by hypocalcemic response, that is, a high dose of NPS
R-568 caused a sustained lowering of serum Ca, whereas a
hypocalcemic response was only transient in the low-dose group
(Fig. 1).
Cancellous bone histomorphometry
Osteitis fibrosa developed in vehicle-treated Nx rats, which was
characterized by overt peritrabecular fibrosis (Fb.V/TV .0.5%)
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dl Fig. 1. Serum PTH and Ca levels in sham-
operated (Sham) and partially nephrectomized
(Nx) rats. Rats were daily treated with vehicle
or NPS R-568 from day 1 to day 30. Serum
samples were obtained at the baseline point on
day 0, before (before R-568) and one hour
after dosing on day 16 (1 hr after R-568), and
at the end of the study on day 31. Symbols are:
(u) sham-vehicle; (o) Nx-vehicle; (s) Nx-low
dose NPS R-568; (m) Nx-high dose NPS R-568.
Values are means 6 SEM (7–8 rats/group as
indicated in Table 1). *P , 0.05, **P , 0.01 vs.
Sham-Vehicle group; #P , 0.05, ##P , 0.01
vs. Nx-Vehicle group.
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and increased osteoblastic and osteoclastic activity (5-fold higher
bone formation rates, 40% greater osteoblast surface and 2.4-fold
greater osteoclast surface than those of the Sham controls,
respectively; Table 2 and Fig. 2). Treatment with NPS R-568 led
to a marked reduction in peritrabecular fibrosis (0.96 6 0.49% to
,0.1%) and decreased incidence of osteitis fibrosa (3 of 8 animals
in the vehicle-dosed Nx group to 0 of 15 animals; P , 0.05,
Fisher’s exact test). The amelioration of osteitis fibrosa by NPS
R-568 was accompanied by lowered bone formation rates and
reduced osteoclast and osteoblast surfaces, although none of the
changes achieved statistical significance (Table 2). Serum PTH
levels were positively correlated with bone formation rate (log-
PTH vs. BFR/TV, r 5 0.57, P , 0.01) and with osteoclast surface
(logPTH vs. Oc.S/BS, r 5 0.50, P , 0.01).
Cortical bone densitometry, biomechanics and morphometry
In vehicle-treated Nx animals, biomechanical competence of
the cortical bone was reduced as documented by a 5% loss in
diaphyseal stiffness and by a 17% decrease in elastic modulus
(Fig. 3 and data not shown). The loss of diaphyseal stiffness was
completely recovered by high dose of NPS R-568 (Fig. 3). Initially,
we speculated that increased stiffness by NPS R-568 could be
due to an increase in volumetric cortical bone mineral density
(vCtBMD) because changes in vCtBMD seemed to parallel those
in stiffness (Fig. 3). However, correlation analysis showed that
stiffness was better correlated with cortical width (r 5 0.63; P ,
0.001) than with vCtBMD (r 5 0.15; NS; Table 3), suggesting a
role for cortical width in increased stiffness. Despite the gain of
vCtBMD, treatment with NPS R-568 did not improve elastic
modulus or ultimate stress (data not shown). Of note, there was
an inverse correlation between vCtBMD and bone formation rate
(r 5 20.53; P , 0.01).
Correlation analysis showed that serum PTH levels were in-
versely correlated with stiffness (r 5 20.59; P , 0.001) and with
ultimate load (r 5 20.76; P , 0.001). Moreover, serum PTH
levels were inversely correlated with cortical width (r 5 20.67;
Fig. 2. Effects of treatment with NPS R-568 for
30 days on peritrabecular fibrosis in the tibial
metaphysis of partially nephrectomized (Nx)
rats. (A) Nx-Vehicle (PTH 5 806 pg/ml); (B)
Nx-low dose NPS R-568 (PTH 5 133 pg/ml).
Panels A and B represent the most severe cases
of secondary hyperparathyroidism in the
vehicle-treated and NPS R-568-treated groups,
respectively. Note overt fibrosis in the vehicle-
treated control, whereas only traces of fibrosis
(arrow heads) in the rat treated with NPS R-
568.
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P , 0.001) and, to a lesser extent, with vCtBMD (r 5 20.37; P ,
0.05).
DISCUSSION
The calcimimetic compound NPS R-568 acts as an agonist at
the cell-surface Ca21 receptor and suppresses PTH secretion [14,
15]. This pharmacological property of NPS R-568 led us to
speculate that the compound may have beneficial effects on bones
of uremic rats with 2°HPT. Partially nephrectomized rats devel-
oped mild, but progressive 2°HPT and osteitis fibrosa, which was
associated with loss of cortical bone strength. In this animal
model, we show that oral administration of NPS R-568 halts or
reverses the development of osteitis fibrosa and restores the loss
of cortical bone strength.
Oral administration of NPS R-568 lowered serum PTH levels
and reduced the incidence of osteitis fibrosa. Osteitis fibrosa is a
high turnover bone disease characterized by abnormally increased
activities of osteoblasts and osteoclasts [1, 2]. Growing evidence
supports the notion that osteitis fibrosa evolves as a direct
consequence of 2°HPT [6–11]. Most of patients with severe
osteitis fibrosa have plasma intact PTH levels above twice the
upper limit of the normal range [reviewed in 27]. In this study,
correlation analysis showed that serum PTH levels were positively
correlated with bone formation rate and with osteoclast surface.
Therefore, it is reasonable to propose that NPS R-568 halts or
reverses the osteitis fibrosa by lowering serum PTH levels thereby
decreasing osteoblastic and osteoclastic activities.
NPS R-568 completely restored the loss of cortical bone
stiffness at the femoral midshaft. Stiffness is the product of bone
size and intrinsic bone strength (that is, elastic modulus) [24, 25].
Intrinsic bone strength is determined by bone material properties
[24, 25]. It was reported that vCtBMD reflects intrinsic bone
strength as an index of cortical bone mineralization [28]. Since
changes in vCtBMD seemed to parallel those in stiffness, we
initially speculated that the increase in stiffness could be due to an
increase in vCtBMD. However, correlation analysis showed that
stiffness was not correlated with vCtBMD, rather correlated with
cortical width. This result suggested that NPS R-568 improved
stiffness primarily by increasing cortical width, which may be
accounted for by reduced bone resorption either at the perios-
teum or at the endosteum [2].
NPS R-568 also restored the loss of vCtBMD, and correlation
analysis showed that vCtBMD was inversely correlated with bone
formation rate. This inverse correlation was reminiscent of the
cortical bone defects seen in primary hyperparathyroidism, which
are ascribed to abnormal skeletal remodeling, that is, expanded
remodeling space, increased cortical porosity or immature miner-
alization [29, 30]. Unlike humans, rats have no complete skeletal
remodeling system. However, analogous defects may account for
the loss of vCtBMD in uremic rats, and NPS R-568 may restore
the vCtBMD loss by alleviating abnormal skeletal remodeling.
Although vCtBMD is generally correlated with intrinsic bone
strength [28], we found no significant increase either in elastic
modulus or in ultimate stress. To test whether NPS R-568 could
improve intrinsic bone strength, prolonged NPS R-568 treatment
is necessary.
The chronic elevation of serum PTH levels could be a risk
factor for poor biomechanical competence of cortical bone.
Cortical bone stiffness and ultimate load were inversely correlated
with serum PTH levels. However, whether or not cortical bone
strength is actually reduced in 2°HPT remains controversial [31,
32]. For example, in patients with 2°HPT, Smith et al found no
reduction in ulnar stiffness in spite of decreased radial BMD [32].
However, this result should be challenged by the finding that
patients with osteitis fibrosa have a relatively high incidence of
fracture [33, 34]. Bone strength is determined by multiple factors
such as architectural dimensions or material properties [24, 25]. In
the present study, we evaluated cortical width as a index of cortical
Table 3. Correlation analysis of serum PTH level, tibial bone formation
rate, and indices of femoral biomechanical competence
PTH BFR Ct.Wi vCtBMD
BFR 0.498b
Ct.Wi 20.675c 20.181
vCtBMD 20.366a 20.530b 0.003
Stiffness 20.586c 20.193 0.634c 0.149
Abbreviations are: PTH, serum parathyroid hormone (before NPS
R-568 gavage on day 16); BFR, bone formation rate (tissue volume-
referent); Ct.Wi, cortical width; vCtBMD, volumetric cortical bone min-
eral density.
a P , 0.05, b P , 0.01, c P , 0.001; Pearson’s correlation coefficient.
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Fig. 3. Effects of treatment with NPS R-568 for 30 days on diaphyseal
stiffness and volumetric cortical bone mineral density (vCtBMD) at the
femoral midshaft in partially nephrectomized (Nx) rats. *P , 0.05 vs.
Sham-Vehicle group; #P , 0.05, ##P , 0.01 vs. Nx-Vehicle group.
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dimensions and vCtBMD as a index of cortical material proper-
ties. Serum PTH levels were inversely correlated with cortical
width and to a lesser extent with vCtBMD. These results indicate
that 2°HPT is a risk factor both for cortical bone loss and poor
biomechanical competence in CRI.
In summary, we demonstrated NPS R-568 has beneficial effects
on bones of uremic Nx rats with 2°HPT: (i) histological evaluation
showed that NPS R-568 halts or reverses the development of
osteitis fibrosa; (ii) biomechanical analysis indicated that NPS
R-568 restores the loss of cortical bone strength; and (iii) corre-
lation analysis suggests that NPS R-568 exerts its beneficial effects
primarily by normalizing serum PTH levels. These results indicate
that NPS R-568 has potential as a therapeutic agent to control
2°HPT and thereby to ameliorate related bone diseases such as
osteitis fibrosa.
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